CClinicalTrials.gg
Status unknownNCT04143633Updated Oct 29, 2019

Low FODMAP Diet on Nutritional Status, Disease Activity and Gut Microbiota in IBS and UC With Normal or Overweight BMI

An interventional study of Low FODMAP diet and Standard diet in IBD - Inflammatory Bowel Disease, IBS - Irritable Bowel Syndrome and UC - Ulcerative Colitis, sponsored by Hospital General de Mexico. Status unknown at 1 site in Mexico. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Hospital General de Mexico · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Feb 2018, registered Oct 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

Gastrointestinal disorders represents 20-50% of referrals to the gastroenterologist; being the most affected womens, youths and older adults. Among these alterations are the Irritable Bowel Syndrome (IBS) and Ulcerative Colitis (UC), which affects the gut causing impaired motility. The pharmacological and nutritional treatment are modified according to the symptomatology and activity of each patients. Currently the implementation of low FODMAP diets for 6 to 8 weeks in patients whith IBS improves symptoms such as bloating, flatulence and abdominal pain. However due to the number of restricted foods a long term attachment could limited the nutritional content, consequently affecting the nutritional status, gut microbiota an quality of life. A low FODMAP diet are useful to improve gastrointestinal symptoms in patients with UC and causes changes in nutritional status.

Read the detailed description

Irritable Bowel Syndrome (IBS) and Ulcerative Colitis (UC) affect principally the gut, causing symptoms that alter intestinal motility, with a multifactorial etiology. The pharmacological and nutritional treatment varies according to the symptoms and activity of each patient. The most commonly used are the standard diet (SD), which excludes foods known as irritants or inflammatory. On the other hand, are the low fodmap diet (LFD) (fermentable oligosaccharides. disaccharides, monosaccharides and polyols), these highly fermentable carbohydrates can pass unabsorbed to the colon and induce the gas production due to the fermentation of gut microbiota and cause symptoms such as: bloating, flatulence, abdominal pain and altered bowel habit. It consists in two stages: first the restriction of all foods that contain fodmaps and second the re exposure in which indicate the introduction of each food restricted before to evaluate the tolerance, for 6 to 8 weeks. Some studies show that the low fodmap diet improve the symptoms in both groups, however because of the restriction and the limited content of foods, they have had risk to present nutritional deficiencies. The aim of the present is to evaluate the effect of a low fodmap diet for 10 weeks on gastrointestinal symptoms, nutritional status and microbiota in patients with IBS and UC.

Methods: a controlled, blinded clinical trial will be conducted in patients who assist to medical monitoring in gastroenterology service with diagnosis of IBS or UC. The sample size was determined with a 0.5 effect size, an alpha error 0.05 and power of 80%, which determined 64 patients for each group (total: 128). After singing the informed consent, will be determined their total energy expenditure (TEE) and consecutively will be assigned an ID previously randomized to SD (\<16 g of fodmaps) or LFD (\<10 g of fodmaps), with a distribution of 55% carbohydrates, 20% proteins and 25% lipids. During the 10 weeks will be three follow-ups, first the basal, intermediate (week 5) and final (10 weeks after), will be performed body composition (RJL Quantum III), anthropometry (waist, hip, arm and chest circumference), gastrointestinal symptoms (ROMA III and Mayo Scale), quality of life (WHOQL-BREF), food frequency and 24-hour reminder and blood chemistry (anemia, hypoalbuminemia, vitamin D, calcium, potassium, c reactive protein, VSG, etc), all of them basal and final.

02

Conditions studied

  • IBD - Inflammatory Bowel Disease
  • IBS - Irritable Bowel Syndrome
  • UC - Ulcerative Colitis

Keywords

  • Irritable Bowel Syndrome
  • Ulcerative Colitis
  • Low FODMAP diet
  • Nutritional status
  • Standard diet
03

In context

Colitis

1,073 studies on the registry are indexed under Colitis; 131 are open to participants now.

This study's planned enrollment of 105 is above the median of 60 across 771 interventional studies indexed under Colitis.

Browse Colitis studies →

Lead sponsor

Hospital General de Mexico is the lead sponsor of 26 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Irritable Bowel Syndrome confirmed by Rome criteria III
  • Ulcerative Colitis confirmed by Mayo Scale
  • Informed Consent signed
  • BMI between 18.5 and 29.9 kg/m2
  • Males and females
  • Age between 18-59 years
  • Mexican patients

Exclusion criteria

Exclusion Criteria:

  • Chron´s disease diagnosed
  • Treatment whith antibiotis during the last two weeks
  • Bowel resection
  • Short bowel syndrome
  • Treatment wihth probiotics or enzimes (A-galactosidase)
  • Pregnancy
  • Nutritional deficiencies or anemia
  • Patients whith diet supplements
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    FODMAP diet in Irritable Bowel Syndrome

    Patients with IBS will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.

    Other: Low FODMAP diet · Other: Standard diet

  • Experimental
    FODMAP diet in Ulcerative Colitis

    Patients with UC will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.

    Other: Low FODMAP diet · Other: Standard diet

  • Active comparator
    FODMAP diet in healthy patients

    Healthy patients will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.

    Other: Low FODMAP diet · Other: Standard diet

Interventions

  • OtherLow FODMAP diet

    The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.

  • OtherStandard diet

    The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.

06

What researchers measure

Primary outcomes

  1. Nutritional status

    Changes from baseline of nutrtitional status measured with cholesterol (mg/dl), triglycerides (mg/dl), albumin (mg/dl), calcium (mg/dl), iron (mg/dl), vitamin B12 (mg/dl), vitamin D (mg/dl), hemoglobin (mg/dl), hematocrit (mg/dl), creatinin (mg/dl) on blood

    Time frame: The patients will be evaluated at weeks 1 and 10

Secondary outcomes

  1. Quality of life in patients with Irritable Bowel Syndrome and Inflammatory Bowel Disease

    Changes from baseline of WHOQOL- BREF (World Health Organization Quality of Life) questionary score (the higher score, the higher quality of life represents) measured with a Likert scale at 10 weeks of nutritional intervention in patients wiht irritable bowel syndrome and inflammatory bowel disease

    Time frame: The patients will be evaluated at weeks 1, 5 and 10

  2. Adherence to treatment

    By 24 hour recalls during the ten weeks of the study and food frequencies at week one, five and ten.

    Time frame: The patients will be evaluated at weeks 1, 5 and 10

  3. Body composition analysis

    Changes from baseline of the percentage of body fat (%), muscle (%) and water (%) at 10 weeks of nutritional intervention, using RJL System IV

    Time frame: The patients will be evaluated at weeks 1, 5 and 10

  4. Gut microbiota with a low FODMAP diet

    The patient will be asked for a stool sample before and after the diet, the microbiota were measure by PCR

    Time frame: Participants will be evaluated at weeks 1, 5 and 10

  5. Blood chemistry

    Changes from baseline glucose, creatinine, high density lipoproteins, low density lipoproteins, cholesterol levels (mg/dL) at 10 weeks of nutritional intervention in patients with IBS and IBD

    Time frame: Participants will be evaluated at weeks 1 and 10

  6. Irritable Bowel Syndrome Severity Score

    Changes from baseline in the presence or absence of gastrointestinal symptoms where the higher the score, more severity of symptoms are assesed using a percentage scale 0-100%, at 10 weeks with low FODMAP diet in patients wih IBS and IBD

    Time frame: Participants will be evaluated at weeks 1, 5 and 10

  7. Gastrointestinal Symptoms Severity

    Changes from baseline of presence or abscense of gastrointestinal symptoms where the higher the score, the higher severity of symptoms (assesed using cualitative scale with options ranging from minimal symptoms to very annoying symptoms) at 10 weeks with low FODMAP diet in patients wih IBS and IBD

    Time frame: Participants will be evaluated at weeks 1, 5 and 10

  8. Anthropometric measurements

    Changes from baseline of arm, waist and hips circumferences in centimeters at 12 weeks of nutritional intervention in patientes with IBS anda IBD

    Time frame: Participants will be evaluated at weeks 1, 5 and 10

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04143633
Lead sponsor
Hospital General de Mexico
Responsible party
Nallely Bueno Hernández (Investigator In Medical Science B, Hospital General de Mexico) — Principal investigator
First posted
Oct 29, 2019
Start date
Feb 10, 2018
Primary completion
Aug 31, 2020 (estimated)
Completion
Aug 31, 2020 (estimated)
Last update
Oct 29, 2019

Study contacts

Nallely Bueno Hernández, PhD
Contact
nallely_bh5@yahoo.com.mx
27892000 ext. 5654
Karen L de León Barrera, B.S
Contact
nut.karendeleon@gmail.com
Nallely Bueno Hernádez, PhD
principal investigator · Hospital General de México

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion